ABSTRACT
Understanding antibiotic resistance mechanisms is critical to designing novel approaches and therapeutics to
combat resistant bacteria. Heteroresistance (HR) is a bacterial phenotype in which an isolate contains a
subpopulation of cells that show a substantial increase in antibiotic resistance compared to the main population.
Many species of bacteria and nearly all classes of antibiotics exhibit this form of phenotypic resistance and there
is evidence from in vitro experiments, mathematical modeling, animal infection models and clinical studies that
the resistant subpopulations can enrich during antibiotic exposure and lead to treatment failure. Recent studies
show that the resistance phenotype in HR is in the majority of cases unstable and in the absence of antibiotic
pressure it rapidly reverts to susceptibility. One major reason for the instability is the occurrence of genetically
unstable tandem gene amplifications of different types of genes that can cause resistance when present at an
increased copy number (e.g., bona fide resistance genes that are normally expressed at low levels, efflux
pumps). Due to the instability, low frequency and transient character, it is challenging to detect and study these
subpopulations and in a clinical microbiology setting this often leads to difficulties in unambiguously classifying
bacteria as susceptible or resistant, which can lead to potential treatment failures. To facilitate the improved
treatment and detection of HR infections, we need to understand in detail the underlying mechanisms and
dynamics by which the resistant sub-populations form, are maintained and recede back to their baseline
frequency in the absence of antibiotic. Specifically, we will ask: what are the key genetic, physiological and
environmental processes and signals that govern the generation of resistant sub-populations and subsequently,
if and how we may modify and interfere with them. To address these questions, we will use clinical isolates of
Enterobacteriaceae (E. coli, K. pneumoniae and Enterobacter spp) and A. baumannii.
At a basic level, this work will significantly broaden our understanding of (i) how traits exhibited by a
subpopulation of cells is generated and can influence behavior and evolution of bacterial populations, (ii) how
HR is generated by CNV, (iii) the mechanisms and dynamics of CNV and (iv) how HR may be predicted from
whole genome sequencing data. This will, in the long-term, provide us with better tools to identify HR and mitigate
its effects in clinical settings and, thereby, improve antibiotic treatment outcome.
Public Health Relevance Statement
PROJECT NARRATIVE
In accordance with RFA-AI-20-001, the project narrative should not be completed for the research project.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
066469933
UEI
S352L5PJLMP8
Project Start Date
05-March-2021
Project End Date
28-February-2026
Budget Start Date
01-March-2024
Budget End Date
28-February-2025
Project Funding Information for 2024
Total Funding
$323,979
Direct Costs
$317,164
Indirect Costs
$6,815
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$323,979
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U19AI158080-04 5647
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U19AI158080-04 5647
Patents
No Patents information available for 5U19AI158080-04 5647
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U19AI158080-04 5647
Clinical Studies
No Clinical Studies information available for 5U19AI158080-04 5647
News and More
Related News Releases
No news release information available for 5U19AI158080-04 5647
History
No Historical information available for 5U19AI158080-04 5647
Similar Projects
No Similar Projects information available for 5U19AI158080-04 5647